Bayer, Nuvisan ink pact to create new research unit in Berlin

Written by Medical Dialogues Bureau Published On 2020-02-14T10:30:45+05:30 | Updated On 14 Feb 2020 10:31 AM IST

Bayer, Nuvisan ink pact to create new research unit in Berlin

The strategic partnership will lay the foundation for a brand-new research entity to be established by Nuvisan in Berlin. At the same time, it will support Bayer's increased focus on the flexibility and productivity of its R&D operating model. Financial terms were not disclosed.

Berlin: Bayer AG recently announced that it entered into a definitive agreement to transfer a large part of its Berlin-based small molecule research unit to Nuvisan, an international service provider for clinical studies, laboratory services and contract manufacturing with several sites and clinics in Germany and France.

The strategic partnership will lay the foundation for a brand-new research entity to be established by Nuvisan in Berlin. At the same time, it will support Bayer's increased focus on the flexibility and productivity of its R&D operating model. Financial terms were not disclosed.

"With Nuvisan we have found an excellent partner with a clear plan to build up a strong full-fledged research unit in Berlin together with our dedicated team of scientists," said Dr Joerg Moeller, Member of the Executive Committee of Bayer AG's Pharmaceuticals Division and Head of Research and Development. "Nuvisan shares our vision that the new research centre can become an important player in research partnering based on the joint know-how and the capabilities of our highly qualified scientists."

The Berlin-based research unit with around 400 workplaces comprises of a fully operational team specialized in small molecule research. The research centre comes with capabilities and capacities spanning the entire drug discovery value chain, including Lead Discovery, Medicinal Chemistry, Pharmacology, Drug Metabolism & Pharmacokinetics, Investigational Toxicology, and Animal Management. Bayer will retain significant research activities in Berlin, which remains the headquarters for the company's Pharmaceuticals Division and one of its major global research sites.

"With these new drug discovery capabilities and capacities, we do not only welcome a high-performance research team but also obtain access to excellent speciality know-how and technology," says Dr Dietrich Bruchmann, CEO and managing partner of Nuvisan. "The acquisition of the research unit and its location at the Bayer R&D campus will create an operational hub in the scientific excellence cluster Berlin and allow us to significantly accelerate the drug development process from discovery to clinical trials."

Bayer and Nuvisan will cooperate closely in the coming years to build the new research centre. The transaction is expected to close mid of 2020 subject to the successful completion of the consultation process with the employee representatives and the preparations for taking over the research activities.

NuvisanBayerresearch entity

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Medical Dialogues Bureau

Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here